PHAXIAM Therapeutics SA

PHAXIAM provides Business and Financial Update for the First Quarter of 2024

15 May 2024 10:45:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024

03 May 2024 11:05:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus

15 Apr 2024 00:30:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024

09 Apr 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)

05 Apr 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Announces 2023 Full-Year Results and Provides Business Update

20 Mar 2024 12:00:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

11 Mar 2024 01:00:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024

05 Mar 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

20 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital - January 31, 2024

06 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

18 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital - December 31, 2023

03 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital - November 30, 2023

06 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

14 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023

07 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

24 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation

23 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2023

23 Oct 2023 11:00:00 By Nasdaq GlobeNewswire